(0.31%) 5 115.93 points
(0.30%) 38 353 points
(0.37%) 15 986 points
(-0.95%) $83.05
(5.36%) $2.03
(0.33%) $2 355.00
(0.47%) $27.67
(4.15%) $960.35
(-0.27%) $0.932
(-0.45%) $10.97
(-0.59%) $0.796
(1.63%) $93.37
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 9.62%
@ $28.73
発行日: 8 4月 2024 @ 22:34
リターン: -11.59%
前回のシグナル: 4月 5 - 00:18
前回のシグナル:
リターン: -1.44 %
Live Chart Being Loaded With Signals
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development...
Stats | |
---|---|
本日の出来高 | 388 608 |
平均出来高 | 1.71M |
時価総額 | 4.69B |
EPS | $0 ( 2024-02-22 ) |
次の収益日 | ( $-0.400 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.43 |
ATR14 | $0.0280 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Kumar Neil | Buy | 313 588 | Restricted Stock Units |
2024-03-12 | Kumar Neil | Buy | 45 140 | Stock Option (right to buy) |
2024-03-12 | Stephenson Brian C | Buy | 107 278 | Restricted Stock Units |
2024-03-12 | Stephenson Brian C | Buy | 15 442 | Stock Option (right to buy) |
2024-03-01 | Scott Randal W. | Sell | 2 500 | Common Stock |
INSIDER POWER |
---|
-18.18 |
Last 100 transactions |
Buy: 1 673 575 | Sell: 2 657 073 |
ボリューム 相関
BridgeBio Pharma Inc 相関
10 最も負の相関 | |
---|---|
NAKD | -0.928 |
NCBS | -0.922 |
GSMG | -0.921 |
PIXY | -0.913 |
SNGX | -0.911 |
LAWS | -0.911 |
GOOD | -0.908 |
VWE | -0.907 |
TSHA | -0.907 |
TRIT | -0.905 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
BridgeBio Pharma Inc 相関 - 通貨/商品
BridgeBio Pharma Inc 財務諸表
Annual | 2023 |
収益: | $9.30M |
総利益: | $6.86M (73.71 %) |
EPS: | $-3.95 |
FY | 2023 |
収益: | $9.30M |
総利益: | $6.86M (73.71 %) |
EPS: | $-3.95 |
FY | 2022 |
収益: | $77.65M |
総利益: | $74.21M (95.58 %) |
EPS: | $-3.35 |
FY | 2021 |
収益: | $69.72M |
総利益: | $66.60M (95.53 %) |
EPS: | $-4.77 |
Financial Reports:
No articles found.
BridgeBio Pharma Inc
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。